Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Gottlieb Avoids Written Commitments to Recusal for 22 Companies

  • Post author:Sam
  • Post published:April 24, 2017
  • Post category:Drug Industry Daily

Scott Gottlieb avoided explicit written commitments to recusing himself from decisions involving nearly two dozen companies named in a senator’s questions. Source: Drug Industry Daily

Continue ReadingGottlieb Avoids Written Commitments to Recusal for 22 Companies

Apotex Urges the FDA to Require Testing of Biosimilars on Intended Patient Population

  • Post author:Sam
  • Post published:April 24, 2017
  • Post category:Drug Industry Daily

Apotex has called on the FDA to require testing on the intended patient population before approving biosimilars. Source: Drug Industry Daily

Continue ReadingApotex Urges the FDA to Require Testing of Biosimilars on Intended Patient Population

Sanofi Sues Mylan Over Business Practices Blocking its EpiPen Competitor

  • Post author:Sam
  • Post published:April 24, 2017
  • Post category:Drug Industry Daily

In a lawsuit filed Monday, Sanofi says Mylan’s anticompetitive business practices blocked its EpiPen competitor, the Auvi-Q, from gaining a foothold in the epinephrine auto-injector market, resulting in hundreds of…

Continue ReadingSanofi Sues Mylan Over Business Practices Blocking its EpiPen Competitor

FDA Orders Texas, Arizona to Destroy Their Execution Drugs

  • Post author:Sam
  • Post published:April 24, 2017
  • Post category:Drug Industry Daily

The FDA has officially notified Texas and Arizona that they must destroy their supplies of execution drugs on the grounds that they were illegally obtained. Source: Drug Industry Daily

Continue ReadingFDA Orders Texas, Arizona to Destroy Their Execution Drugs

FDA Allows In Vitro Studies to Demonstrate Naloxone Bioequivalence

  • Post author:Sam
  • Post published:April 21, 2017
  • Post category:Drug Industry Daily

For the development of generic versions of naloxone, an emergency nasal spray treatment for opioid overdoses, the FDA said it will allow sponsors to demonstrate bioequivalence using solely in vitro…

Continue ReadingFDA Allows In Vitro Studies to Demonstrate Naloxone Bioequivalence

EMA’s CHMP Recommends 11 Medicines for Approval, including Three Biosimilars

  • Post author:Sam
  • Post published:April 21, 2017
  • Post category:Drug Industry Daily

The European Medicines Agency Committee for Medicinal Products for Human Use recommended 11 medicines for approval, including four orphan drugs and three biosimilars. Source: Drug Industry Daily

Continue ReadingEMA’s CHMP Recommends 11 Medicines for Approval, including Three Biosimilars

FDA Approves Second Remicade Biosimilar: Samsung Bioepis’ Renflexis

  • Post author:Sam
  • Post published:April 21, 2017
  • Post category:Drug Industry Daily

The FDA approved Renflexis, a biosimilar of Remicade, in several indications including rheumatoid arthritis, plaque psoriasis and Crohn’s disease. Source: Drug Industry Daily

Continue ReadingFDA Approves Second Remicade Biosimilar: Samsung Bioepis’ Renflexis

MHRA Outlines Regulatory Goals in Preparation for Leaving the EU

  • Post author:Sam
  • Post published:April 21, 2017
  • Post category:Drug Industry Daily

The U.K.’s Medicines and Healthcare products Regulatory Agency laid out its top 10 priorities for 2017 and 2018 — including developing a model for the agency’s future, post-Brexit. Source: Drug…

Continue ReadingMHRA Outlines Regulatory Goals in Preparation for Leaving the EU

FDA’s Unapproved-Use Communication Rules Prompt First Amendment Worries

  • Post author:Sam
  • Post published:April 21, 2017
  • Post category:Drug Industry Daily

An FDA memo outlining restrictions on communications over unapproved uses could restrict the flow of important information, and conflict with a company’s freedom of speech, say drugmakers and industry groups.…

Continue ReadingFDA’s Unapproved-Use Communication Rules Prompt First Amendment Worries

SCYNEXIS, Inc. To Host A Conference Call To Discuss Lead Anti-Infective Candidate SCY-078 Data Presented At

  • Post author:Sam
  • Post published:April 20, 2017
  • Post category:BioPharma

  Life Sciences Jobs   ... Source: BioSpace

Continue ReadingSCYNEXIS, Inc. To Host A Conference Call To Discuss Lead Anti-Infective Candidate SCY-078 Data Presented At
  • Go to the previous page
  • 1
  • …
  • 472
  • 473
  • 474
  • 475
  • 476
  • 477
  • 478
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.